KING'S COLLEGE LONDON Patent applications |
Patent application number | Title | Published |
20160123878 | PLASMONIC HYDROGEN DETECTION - A plasmonic hydrogen detector and method of constructing a plasmonic hydrogen detector. The plasmonic hydrogen detector comprises: a structure comprising a support and a plurality of nanostructure elements. The plurality of nanostructure elements comprise a plasmonic material and a hydrogen sensitive material. The plurality of nanostructure elements are configured on the support to allow the structure to act as a plasmonic metamaterial. The hydrogen sensitive material is configured to cause a change in permittivity of the plasmonic metamaterial in the presence of hydrogen. Aspects and embodiments described recognise that use of a plasmonic metamaterial as a hydrogen detector can result in a highly sensitive detector. That sensitivity stems from the sensitivity of strong plasmonic coupling between individual nanostructure elements in the metamaterial to external perturbations, for example, as a result of a physical or chemical environmental change. | 05-05-2016 |
20160103135 | METHOD - The invention provides a method of detecting the presence of anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and detecting the binding or absence of binding of antibodies to said recombinant MHC molecules. This method allows the detection and/or identification of one or more specific MHC particularly HLA allele antibodies. | 04-14-2016 |
20160046699 | PEPTIDES AND BINDING PARTNERS THEREFOR - The invention provides a peptide obtainable from | 02-18-2016 |
20150260622 | METHODS OF DEPLETING ANTIBODIES DIRECTED TOWARDS MAJOR HISTOCOMPATIBILITY COMPLEX - The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the sample have bound. This method allows the depletion of one or more specific MHC particularly HLA allele antibodies from a sample. | 09-17-2015 |
20150216833 | Therapeutic for Treating Inflammatory Lung Disorders - A calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulisers or inhalers including the antagonist are also described. | 08-06-2015 |
20150104442 | PHOSPHOCOFILIN: COFILIN CO-LOCALIZATION INTENSITY AS A PREDICTOR OF METASTATIC RECURRENCE - Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided. | 04-16-2015 |
20150064107 | IMAGING AGENT - The invention relates to imaging agents, and in particular to multi-modal nanoparticle (NPIA) imaging agents offering magnetic, radionuclide and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). The invention extends to these new types of agents per se, and to uses of such agents in various biomedical applications, such as in therapy and in diagnosis. | 03-05-2015 |
20150051097 | Methods for Screening Inhibitors of Tau Phosphorylation By Casein Kinase I - Methods of screening for candidate compounds capable of inhibiting activity of fyn in phosphorylating tau protein at Y394 or binding to fyn to inhibit interaction with tau protein at Y394, including determining whether, and optionally the extent, the candidate compounds have these capabilities under conditions where fyn has these capabilities in the absence of the candidate compound. Methods of screening for substances capable of promoting dephosphorylation of tau protein by a phosphatase at a site of tau protein including contacting a candidate substance, the tau protein and a phosphatase capable of dephosphorylating the tau protein under conditions where the phosphatase is capable of dephosphorylating the site in absence of the candidate substance, where the kinase is fyn; determining whether, and optionally the extent, the candidate substance promotes dephosphorylation of the tau protein at the site; and selecting the candidate substance which promotes dephosphorylation of the tau protein the sites. | 02-19-2015 |
20150037394 | DRUG DELIVERY FORMULATIONS - Mixtures of C | 02-05-2015 |
20140350462 | CONTINUUM MANIPULATOR - Embodiments of the present invention provide a continuum manipulator that can be used, for example, as a steerable catheter tip. The manipulator of the embodiments comprises a plurality of segments arranged in a stack, which is then able to bend in a range of directions away from the long axis of the stack. In one embodiment the segments include a helical portion which winds in the direction of the long axis of the stack, and can thus bend away from the long axis in any direction. In another embodiment the segments include a backbone portion with cantilevered rings extending from the backbone portion, separated by bending gaps which allow the segment to bend in a range of directions away from the backbone portion so that the bending gap between the rings closes. In some embodiments a carbon fibre rod is included as a backbone for the stack, to minimise hysteresis and improve repeatability of bending. In addition, in embodiments of the invention tendon control channels are provided formed within the segments, through which tendon control wires extend to apply compression and/or bending forces to the stack Having the control channels formed internally to the stack strengthens the stack and makes the stacked structure conform to the channel(s). In particular unwanted twisting of the tip of the stack can be prevented and torquability can be improved. | 11-27-2014 |
20140322246 | IGE ANTI-HMW-MAA Antibody - In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fcε receptor. | 10-30-2014 |
20140308694 | ENDODONTIC IMAGING - A method and apparatus for detecting the presence of the viable cells in an endodontic sample in or taken from an endodontic cavity in the tooth, such as the root canal, enables the rapid and low cost identification of the presence or absence of bacteria or other viable cell tissue in the endodontic space by first incubating a viable cell indicator with an endodontic sample for a pre-determined period suitable for chair-side test and then measuring and/or detecting a change in a parameter (e.g. fluorescence) associated with the viable cell indicator. Thereby, the required level of root canal treatment can be reached which minimizes the risk of re-infection without the time, cost and potentially harm of over-preparation and over treatment by the dental surgeon or of a re-treatment. | 10-16-2014 |
20140273267 | Methods of depleting antibodies directed towards major histocompatibility complex - The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the sample have bound. This method allows the depletion of one or more specific MHC particularly HLA allele antibodies from a sample. | 09-18-2014 |
20140220694 | METHODS AND COMPOSITIONS RELATING TO PLATELET SENSITIVITY - The invention identifies and describes proteins that are differentially expressed in platelets resistant to anti-platelet agents such as aspirin (acetylsalicyclic acid) compared to those platelets that are sensitive to such agents. Methods for determining further such differentially expressed proteins and methods for determining an individual's sensitivity to anti-platelet agents, such as aspirin, prior to administration. | 08-07-2014 |
20140212906 | Screening Method - A method for screening for variant peptides uses mass spectrometry (MS). A system and a kit may be used for performing the method. Proteins in a sample are digested to form a defined series of peptides. The defined series of peptides are ionized. The ionized species are subjected to collision induced dissociation. Species of known mass/charge ratio are detected to confirm the presence of the protein variant in the original sample. | 07-31-2014 |
20140178857 | Method - The invention provides a method of detecting the presence of anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and detecting the binding or absence of binding of antibodies to said recombinant MHC molecules. This method allows the detection and/or identification of one or more specific MHC particularly HLA allele antibodies. | 06-26-2014 |
20140065069 | Materials and Methods Relating to Cardiovascular Imaging - The invention provides conjugates for imaging plaques, such as cardiovascular plaques, as well as associated pharmaceutical compositions. Other aspects of the invention include methods for administering and imaging such conjugates and compositions, and using the imaging to characterise plaques. The conjugates of the invention distinguish between tropoelastin and elastin in plaques. The presence of tropoelastin can act as an indication that a plaque is liable to rupture or erode. Such information allows assessment of disease progression and response to treatment. | 03-06-2014 |
20140056810 | CONJUGATES AND THEIR USES IN MOLECULAR IMAGING - The present invention relates to bifunctional compounds, the bifunctional compounds for use in molecular imaging and therapy, methods of molecular imaging using the bifunctional compounds and kits including the bifunctional compounds for use molecular imaging. The bifunctional compounds have a tripodal hydroxypyridinone chelating portion and may be conjugated to a targeting group so that the compounds target specific cells or tissues in a subject. | 02-27-2014 |
20140024551 | MIRNA-Based Detection Methods - The present invention relates to a method of detecting diabetes and associated complications. The present invention also relates to a method of predicting diabetes. The present invention also relates to a method of detecting and/or predicting vascular disorders and cardiovascular disorders. The present invention also relates to kits for performing the methods of the present invention. | 01-23-2014 |
20140018256 | METHOD OF DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides a method for diagnosing an autism spectrum disorder (ASD), or predisposition to develop an ASD, in a subject, which comprises the step of investigating a set of single nucleotide polymorphisms (SNPs) in a sample from the subject, wherein the number of SNPs in the set is such that the method can diagnose ASD with at least 70% accuracy. The invention also provides a kit for diagnosing an ASD, or predisposition to develop an ASD, in a subject, which comprises a plurality of primer pairs or probes capable of investigating such a set of SNPs in a sample from a subject, and a method for making such a kit. | 01-16-2014 |
20130208272 | METHOD AND APPARATUS FOR NON-RESONANT BACKGROUND REDUCTION IN COHERENT ANTI-STOKES RAMAN SCATTERING (CARS) SPECTROSCOPY - Embodiments of the invention provide a simple and robust system that allows non-resonant background to be removed from anti-Stokes signals generated during coherent anti-Stokes Raman spectroscopy (CARS) even when using cheaper laser systems, which do not have transform limited pulses. In particular, resonant CARS signals have a real and imaginary component. The imaginary component is directly related to the spontaneous Raman spectrum, for which there are already large spectral databases to allow chemical identification. The NRB signal, on the other hand, only has a real component. Within embodiments of the invention we recover the imaginary component of the entire CARS signal by simultaneously generating two CARS signals at orthogonal polarisations: one has the imaginary components destructively interfering with (i.e. subtracted from) the real components, the other has them constructively interfering. Measuring these two polarisations and subtracting them therefore cancels out the real part of the signal, leaving only the imaginary components. | 08-15-2013 |
20130171644 | COINCIDENCE DETECTION - The invention relates to a method of detecting the coincidence of two biomolecular structures in a solid phase sample, said method comprising: (i) providing a first and a second fusion protein, each fusion protein comprising (a) a detection domain, said detection domain comprising a DNA binding domain; said detection domain capable of binding a cognate specific nucleotide sequence in co-operation with a further detection domain; (b) a recognition domain, said recognition domain capable of binding a target biomolecular structure; and (c) a connector domain; said connector domain being fused at one end to the detection domain and being fused at the other end to the recognition domain; wherein at least two of (a), (b) and (c) are heterologous to one another; wherein the recognition domains of said first and said second fusion proteins are capable of binding to first and second biomolecular structures; (ii) contacting the sample with said first and second fusion proteins; (iii) incubating to allow binding; (iv) removing unbound fusion protein; (v) contacting the sample with nucleic acid comprising said cognate specific nucleotide sequence; (vi) incubating to allow heterotrimeric binding of the nucleic acid; (vii) detecting nucleic acid bound to the sample wherein detection of nucleic acid in step; (vii) indicates that the two biomolecular structures are present coincidentally in said sample. | 07-04-2013 |
20130157375 | COMPOUND - In one aspect, there is provided a fluorescent iron-binding compound bound to a solid phase. Also provided is a method for detecting non-transferrin bound iron in a sample, comprising contacting the sample with a fluorescent iron-binding compound bound to a solid phase and detecting a fluorescent signal derived from the fluorescent iron-binding compound bound to the solid phase, wherein the fluorescent signal is indicative of non-transferrin bound iron levels in the sample. Further provided is use of a fluorescent iron-binding compound bound to a solid phase to detect non-transferrin bound iron in a sample. | 06-20-2013 |
20130123133 | SCREENING METHODS - The present invention provides materials and methods relating to screening for compounds useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets. | 05-16-2013 |
20130119687 | ROBOTIC HAND WITH PALM SECTION COMPRISING SEVERAL PARTS ABLE TO MOVE RELATIVE TO EACH OTHER - An improved robotic hand in which the palm section enables it to be capable of a wide range of movement with the ability to have good precision and control. The palm section consists of a plurality of parts which are able to move or flex relative to each other. Preferably, it is constructed as five bar spherical linkage having two degrees of freedom. | 05-16-2013 |
20130029882 | Nucleic Acids and Libraries - The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3′UTR. The invention also relates to methods for making and screening libraries. | 01-31-2013 |
20130029876 | Nucleic Acids and Libraries - The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3′UTR. The invention also relates to methods for making and screening libraries. | 01-31-2013 |
20130017562 | Assay for Vascular CalcificationAANM Shanahan; Catherine M.AACI LondonAACO GBAAGP Shanahan; Catherine M. London GBAANM Kapustin; Alexander N.AACI LondonAACO GBAAGP Kapustin; Alexander N. London GB - An assay for identifying an individual having or at risk of developing vascular calcification, said assay comprising obtaining a blood sample from an individual and measuring the level of a vesicular compound in a matrix vesicle present in the blood sample from said individual; wherein an increased level of said compound indicates an individual at risk of developing vascular calcification. | 01-17-2013 |
20120315653 | SEPSIS TEST - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection. | 12-13-2012 |
20120269736 | MICELLAR COMPOSITIONS FOR USE IN BIOLOGICAL APPLICATIONS - This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent. | 10-25-2012 |
20120251446 | Peptide Conjugates Comprising Polyhistidine Sequence and Free Cysteine and Their Uses in Imaging - Bioconjugates for use in imaging are disclosed include a linker sequence fused to a polypeptide capable of binding a target in a biological system. The linker sequence is designed so that it is capable of being radiolabelled, e.g. with a complex comprising a radionuclide, via a free cysteine residue and the polyhistidine sequence in the label that are both capable of simultaneously binding to a complex comprising the radionuclide. These interactions can improve significantly the rate and efficiency of radiolabelling compared to either protein with the His-tag or the free cysteine alone. Optionally, the free cysteine residue provides a site which can be covalently bonded to a moiety such as a second label, in a site-specific manner. | 10-04-2012 |
20120232251 | GLUCOSE SENSOR - The invention relates to a glucose binding protein comprising amino acid mutations relative to the wild type sequence at the following positions: (i) H 152, (ii) A213; and (iii) L238 wherein the mutation at position H 152 is H152C. The invention further relates to such a glucose binding protein comprising the mutations H152C, A213R and L238S, in particular when linked to an environmentally sensitive dye such as badan. | 09-13-2012 |
20120232014 | ANTITHROMBOTIC COMPOUNDS - A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation. Also disclosed is an organ, tissue or cell which has been perfused with the compounds. | 09-13-2012 |
20120205933 | ROBOTIC HAND WITH PALM SECTION COMPRISING SEVERAL PARTS ABLE TO MOVE RELATIVE TO EACH OTHER - An improved robotic hand in which the palm section enables it to be capable of a wide range of movement with the ability to have good precision and control. The palm section consists of a plurality of parts which are able to move or flex relative to each other. Preferably, it is constructed as five bar spherical linkage having two degrees of freedom. | 08-16-2012 |
20120157422 | MARKER - The invention provides a method for identifying whether a pregnant subject has an increased risk of preterm labour comprising measuring the progesterone concentration in a sample obtained from the subject, wherein a reduced progesterone concentration is indicative of an increased risk of preterm labour and delivery. | 06-21-2012 |
20120156702 | CMYBP-C AND MLC2 AS DIAGNOSTIC MARKERS OF CARDIAC INJURY - The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject. | 06-21-2012 |
20120149737 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment. | 06-14-2012 |
20120077771 | COMPOSITIONS FOR USE IN CARDIOPLEGIA COMPRISING ESMOLOL AND ADENOSINE - The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions. | 03-29-2012 |
20120071337 | METHODS - The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated. | 03-22-2012 |
20120058917 | Nucleic Acids and Libraries - The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3′UTR. The invention also relates to methods for making and screening libraries. | 03-08-2012 |
20110212076 | Viral Therapeutic - The invention provides a method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell. Suitably ps20 is inhibited by contacting said cell with an antibody capable of binding to ps20 polypeptide. Suitably said antibody is ps20 neutralising antibody. The invention also provides antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding ps20 polypeptide, or antisense ps20 polynucleotide for use as a medicament for viral infection. The invention also provides a method of identifying an agent for inhibiting a viral infection, comprising determining level of ps20 expression in first and second samples, the first contacted with test agent; and comparing the level of ps20 expression in said first and second samples; wherein lower level of ps20 expression in said first sample relative to said second sample identifies test agent as an agent for inhibiting a viral infection. | 09-01-2011 |
20110210728 | ENHANCING SIGNALS - A method of testing a sample comprising the steps of: applying an excitation to the sample; detecting a response signal from the sample; processing a first part and a second part of the response signal; and determining from the second part of the response signal information with which to enhance the first part of the response signal. | 09-01-2011 |
20110117523 | ABRASIVE AGENTS - The present invention relates to the use of a polyalkenoate acid, such as polyacrylic acid or polymaleic acid, in the manufacture of an air abrasive agent for use in conditioning dental tissue, methods of using such air abrasive agents, dental compositions comprising a polyalkenoate acid, air abrasive agents comprising a polyalkenoate acid and at least one of a bioactive glass, a glycine salt, baking soda and alumina, methods of treatment and/or prophylaxis using an air abrasive agent comprising a polyalkenoate acid. | 05-19-2011 |
20110025327 | METHOD FOR RADIOFREQUENCY MAPPING IN MAGNETIC RESONANCE IMAGING - A method of mapping a radio frequency magnetic field transmitted to a magnetic resonance imaging specimen. The method comprises the steps of: applying a first radio frequency pulse having a first excitation angle to the specimen and at a first time period after applying the first pulse applying one or more second radio frequency pulses each having a second excitation angle to the specimen, with a second time period between second pulses, to obtain a first data set defining a first sample of an image space; applying one or more third radio frequency pulses each having a third excitation angle to the specimen, with a third time period between third pulses, to obtain a second data set defining a second sample of the image space; applying one or more fourth radio frequency pulses each having a fourth excitation angle to the specimen, with a fourth time period between fourth pulses, to obtain a third data set defining a third sample of the image space; wherein the fourth excitation angle is different to the third excitation angle and/or the fourth time period is different to the third time period; calculating a magnetic field map data from at the three data sets; and outputting the magnetic field map data. | 02-03-2011 |
20110019608 | METHOD AND SYSTEM FOR FREQUENCY RELAYING - A method of transmitting data across an electronic data communication system comprising a plurality of terminals that can send and receive data in the form of electromagnetic waves to and from at least one of the terminals, which method comprises the steps of: (a) identifying at least one control terminal, at least one target terminal and at least two relaying terminals from the plurality of terminals; and (b) using the control terminal to instruct the at least two relaying terminals to receive and relay data intended for the at least one target terminal, so that the at least one target terminal can receive data directly from at least one terminal and from the at least two relaying terminals, thereby increasing capacity of the system. | 01-27-2011 |
20100297011 | ISOLATED PEPTIDES AND USES THEREOF - The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (T1DM). | 11-25-2010 |
20100291063 | PROTEASE INHIBITION - The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment. | 11-18-2010 |
20100273199 | Methods and Compositions - The invention relates to a method for aiding the diagnosis of a disorder in a subject, said method comprising; providing a sample from said subject wherein the sample comprises blood; assaying at least two characteristics of said sample, said characteristics selected from: the structural composition of a polypeptide comprised by said sample; a metabolite comprised by said sample; and a catalytic activity comprised by said sample, wherein each of said at least two characteristics is determined from a multiplexed analysis of the same sample. The invention also relates to certain compositions. | 10-28-2010 |
20100266493 | AGONIST ANTIBODIES AGAINST TSHR - The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies. | 10-21-2010 |
20100247663 | MICROSPHERES - The invention relates to the production of microspheres having radial pores using thermally induced phase separation, especially microspheres for use in tissue engineering. | 09-30-2010 |
20100216664 | Method - The present invention relates, in one aspect, to a method for determining the severity of a disease attributed to at least one genetic mutation in one or more of the genes encoding haemoglobin polypeptide chains, comprising the steps of: (a) providing a sample from said subject; and (b) determining the presence of one or more diagnostic markers:
| 08-26-2010 |
20100216119 | Diagnostic Methods for HIV Infection - The invention relates to a method of aiding the diagnosis of a human immunodeficiency virus infection in a subject, said method comprising (i) providing a sample from the subject (ii) determining the level of ps20 in said sample (iii) comparing the level of ps20 of (ii) with the level of ps20 in an uninfected reference sample, wherein a higher level of ps20 in the sample from the subject compared to the uninfected reference sample indicates an increased likelihood of human immunodeficiency virus infection in said subject. The invention also relates to methods for assessing susceptibility of a subject to human immunodeficiency virus infection. Most suitably the ps20 level is determined via binding by an anti-ps20 antibody such as the 107 antibody. The invention also relates to kits for use in said methods. | 08-26-2010 |
20100159473 | Peptide Standards - The invention relates to methods for making a peptide standard for mass spectrometry said method comprising (a) identifying endopeptidase cleavage sites in a parent polypeptide sequence of interest; (b) selecting peptide sequences from said parent polypeptide which are defined by endopeptidase cleavage sites of step (a); (c) adding a C-terminal extension to each selected sequence; wherein if the endopeptidase cleavage site is C-terminal to its recognition sequence then the C-terminal extension comprises 1 to 6 amino acids, wherein if the endopeptidase cleavage site is N-terminal to its recognition sequence then the C-terminal extension comprises said recognition sequence, wherein if the endopeptidase cleavage site is within its recognition sequence then the C-terminal extension comprises the remainder of said recognition sequence C-terminal to the cleavage site; and (d) synthesising a peptide having the extended amino acid sequence of step (c). The invention also relates to peptide standards and methods of analysing samples. | 06-24-2010 |
20100047779 | BIOMARKERS - The present invention provides circulating biomarkers for conditions associated with metabolic syndrome, including diabetes mellitus, hypertension and congestive heart failure. The biomarkers include plasma DNA, neuron-specific enolase, 11β-hydroxysteroid dehydrogenase, rhodopsin, retinoschisin, RPE65 and cardiac troponin T. Methods and kits for detecting these biomarkers in the prediction, monitoring and diagnosing of disease are provided, particularly for determining mRNA levels thereof in a subject's blood. | 02-25-2010 |
20100029624 | Male Contraceptive - A compound having formula I. R | 02-04-2010 |
20090317831 | Sepsis Test - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection. | 12-24-2009 |
20090317457 | ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN B-4 - The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier. | 12-24-2009 |
20090281026 | Use of BiP or a Variant, Homologue, Derivative or Fragment Thereof in the Manufacture of a Medicament for the Prevention or Treatment of Bone Loss or Bone Resorption - The present invention relates to the use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption. | 11-12-2009 |
20080317717 | ANTI-HEPATITIS B VIRUS RIBOZYMAL NUCLEIC ACID - This invention relates to ribozymes which cleave Hepatitis B Virus (HBV) at CUC sites. Suitable ribozymes may, for example, cleave at GGCUCUCUCGUCCC, CCUCAGCUCUGUAUCG or GAGGACUCUUGGA recognition sequences in HBV RNA. Ribozymal DNA, vector systems and pharmaceutical compositions are provided which may be useful, for example, in the treatment of HBV infection. | 12-25-2008 |
20080280345 | Screening Method - The present invention relates to a method for screening for variant peptides using mass spectrometry (MS). The present invention also relates to a system and a kit for performing the method. | 11-13-2008 |